Research doesn't generate immediate revenue. GNBT needs that S-1 money to jumpstart its revenue producers.
NGIO might make it work using money generated in the IPO. If successful, the vaccine and virus test instruments will generate the money needed for long-term research.
(0)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links